title: An update on breast cancer prevention trials.
abstract: In recent years, the question of whether breast cancer can be prevented has been examined in a number of large clinical trials, employing either selective estrogen receptor modifiers such as tamoxifen and raloxifene or aromatase inhibitors. In this paper, we review the most prominent studies, all of which are either under way or in follow-up.
authors.affiliation: National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, USA. larry.wickerham@nsabp.org
authors.forename: D L
authors.initials: DL
authors.lastname: Wickerham
authors.forename: V
authors.initials: V
authors.lastname: Fourchotte
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000201:enzymology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride